Track Milestone Pharmaceuticals Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Milestone Pharmaceuticals Inc. MIST · Stock Open Milestone Pharmaceuticals Inc. in new tab

0.5200 USD
EPS
-0.68
P/B
5.15
ROE
-35522.62
Beta
1.07
Target Price
5.57 USD
Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc.

🧾 Earnings Recap – Q3 2026

Milestone shares fell 20.6% after earnings, as investors likely focused on the gap between launch growth and the company’s need to cut costs: CARDAMYST prescriptions rose 50% quarter over quarter, but Milestone is reducing operating expenses by about 30% and restructuring its commercial organization. The transcript does not provide a revised sales outlook; the cost measures and leadership departures suggest the launch has yet to support the prior operating structure.

  • CARDAMYST generated approximately 1,800 prescriptions in Q3, up 50% from Q2; cumulative prescriptions since launch reached approximately 3,400.
  • About 750 unique healthcare providers prescribed the drug in Q3, a 16% increase from Q2; cumulative prescribers reached approximately 1,600.
  • Formulary coverage rose to approximately two-thirds of commercially covered lives, from about 50% reported on the prior call.
  • Milestone expects cost measures to reduce operating expenses by approximately 30%, with implementation targeted for completion by Q1 2027; it expects about $2 million in one-time charges.
  • The company said the measures and an extended payment-in-kind interest period are expected to extend cash runway into late 2028, through the anticipated ReVeRA-301 Phase III readout in the second half of 2028.
📅
Loading chart...
Key Metrics
Earnings dateMarch 19, 2027
EPS-0.68
Book Value0.13
Price to Book5.15
Debt/Equity778.53
% Insiders0.696%
Estimates
Forward P/E-0.85
Forward EPS-0.78
Target Mean Price5.57

DCF valuation

Model fair value for Milestone Pharmaceuticals Inc. (MIST)
Result
Sign in to run the valuation for MIST.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus Strong buy · mean target 5.57 USD (low 1.00, high 8.00) · as of 11 Nov 2026
Low 1.00
Mean 5.57
High 8.00
Price 0.5200
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Milestone Pharmaceuticals Inc. Logo Milestone Pharmaceuticals Inc. Analysis (MIST)

United States Financials Official Website Stock

Is Milestone Pharmaceuticals Inc. a good investment? Milestone Pharmaceuticals Inc. (MIST) is currently trading at 0.5200 USD. Market analysts have a consensus price target of 5.57 USD. This suggests a potential upside from current levels.

Earnings Schedule: Milestone Pharmaceuticals Inc. is expected to release its next earnings report on March 19, 2027. The market consensus estimate for Forward EPS is -0.78.

Investor FAQ

Does Milestone Pharmaceuticals Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Milestone Pharmaceuticals Inc.?

Milestone Pharmaceuticals Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 19, 2027. The company currently has a trailing EPS of -0.68.

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Exchange Ticker
NMS (United States) MIST
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion